# DESCRIPTION

## FIELD OF THE INVENTION

- relate to means for vaccination

## BACKGROUND OF THE INVENTION

- introduce Yersinia pestis and plague
- motivate vaccination against plague
- summarize limitations of existing vaccines
- introduce Derbise et al. 2012

## SUMMARY OF THE INVENTION

- define subject-matter of application
- describe Yersinia pseudotuberculosis cells
- specify nucleic acid coding for Caf1 polypeptide
- describe advantages of genetically attenuated cells
- highlight immunogenicity and vaccine applications
- claim high vaccination efficacy

## DETAILED DESCRIPTION OF THE INVENTION

- introduce Yersinia pseudotuberculosis cell
- describe recombinant cell
- specify serotype of Y. pseudotuberculosis cell
- describe availability of Y. pseudotuberculosis strains
- motivate Y. pseudotuberculosis infection
- describe symptoms of Y. pseudotuberculosis infection
- introduce avirulent Y. pseudotuberculosis cell
- describe method of attenuation
- specify genetic attenuation
- specify irreversible attenuation
- describe deletion of genes for attenuation
- specify genes for deletion
- describe method of gene deletion
- specify illustrative gene sequences
- describe alternative embodiment of attenuation
- specify killed or live cell
- describe advantageous embodiment of live cell
- introduce Yersinia pestis Caf1 polypeptide
- describe surface-expression of Y. pestis Caf1 polypeptide
- specify Y. pestis F1 protein
- describe biogenesis process of Y. pestis F1 protein
- specify biotypes of Y. pestis
- describe availability of Y. pestis strains
- introduce cloning of caf1 gene
- specify illustrative Y. pestis Caf1 sequence
- describe antigenic fragments of Y. pestis Caf1
- specify nucleic acid coding for Y. pestis Caf1 polypeptide
- describe insertion of nucleic acid into chromosome
- specify means for inserting nucleic acid
- describe transposon means
- specify illustrative transposon means
- describe insertion of nucleic acid by transposition
- specify advantageous embodiment of transposition
- describe expression of Y. pestis Caf1 polypeptide at surface
- specify oligomer of Y. pestis Caf1 polypeptide
- describe Y. pestis Caf1 polypeptide expression
- introduce Y. pseudotuberculosis cell
- describe surface expression of Y. pestis F1 protein
- describe Y. pestis F1 capsule
- describe recognition by anti-Y. pestis F1 monoclonal antibody
- describe nucleic acid coding for Y. pestis Caf1 polypeptide
- describe gene for chaperone/usher pathway
- describe gene for surface expression
- describe operon structure
- describe Y. pestis Caf1M protein sequence
- describe Y. pestis Caf1A protein sequence
- describe Y. pestis Caf1R protein sequence
- describe avirulent Y. pseudotuberculosis cell
- describe genetically attenuated Y. pseudotuberculosis cell
- describe deletion or inactivation of genes
- describe chromosomal insertion of nucleic acid
- describe Y. pseudotuberculosis strain
- describe immunogen use
- describe administration route
- describe immunologic adjuvant use
- describe composition or vaccine
- describe pharmaceutical composition
- describe immunogenic composition or vaccine
- describe vehicle or formulation
- describe method of treatment
- describe method for preventing or treating Y. pestis infection
- describe method of administering immunogenic composition or vaccine
- describe intended use
- describe in vitro use of Y. pseudotuberculosis cell
- define CNCM
- define CRBIP
- define NCTC
- define DSMZ
- define ATCC
- define terms
- describe term "comprising"
- describe term "consisting of"
- describe term "essentially consisting of"
- describe relationship between terms
- describe organization of application
- describe combinations of sections and embodiments
- describe incorporation of references
- describe examples
- describe illustration
- describe limitation

### EXAMPLES

- produce Y. pseudotuberculosis strain
- clone Y. pestis F1-encoding caf operon
- introduce caf operon into attenuated Y. pseudotuberculosis strain
- generate encapsulated derivative of attenuated Y. pseudotuberculosis strain
- test oral inoculation of V674pF1
- evaluate humoral and cellular components of immunity
- discuss limitations of V674pF1
- generate another form of encapsulated derivative
- compare V674pF1 and V674TnF1 for stability of F1 production
- discuss potential residual virulence of the strain
- evaluate protective efficacy
- describe ethics of animal experiments
- introduce Y. pestis strain CO92
- describe genome sequence of Y. pestis strain CO92
- introduce Y. pseudotuberculosis strains
- describe construction of V674TnF1
- verify F1 capsule production
- discuss attenuation of virulence
- test virulence of V674TnF1 after intragastric administration
- test virulence of V674TnF1 after subcutaneous administration
- evaluate persistence of V674TnF1 in mice
- evaluate protection conferred against bubonic and pneumonic forms of plague

## CONCLUSIONS

- summarize advantages of V674TnF1
- describe vaccine efficacy
- compare with V674pF1
- discuss administration routes

